PI3K/AKT/mTOR信号通路及相关表观遗传调控机制在结直肠癌中的研究进展

doi:10.3969/j.issn.1004-616x.2023.02.012

摘要/Abstract

摘要： 随着对推动结直肠癌发展的相关分子变化和基因组标志物认识的持续加深，分子靶向治疗逐渐进入了大众的视野。磷脂酰肌醇-3-激酶(PI3K)/蛋白激酶B(PKB/AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路是参与多种复杂细胞进程的重要信号通路之一。它的异常激活可调节许多癌症中的细胞自噬、上皮间质转化、细胞凋亡、化学抗性及肿瘤细胞和组织转移。目前该通路是抗结直肠癌治疗的一个有吸引力的靶点。此外，新的证据表明，表观遗传调控机制可以直接或间接参与调节PI3K/AKT/mTOR信号通路。这篇综述重点关注了这一途径在结直肠癌发展、预后和转移中的作用，尤其是表观遗传改变，包括DNA甲基化、组蛋白修饰和非编码RNA的影响，为下一步结直肠癌的精准治疗提供临床思路。

关键词: 结直肠癌, PI3K/AKT/mTOR信号通路, 表观遗传, 靶向治疗

中图分类号:

R246.5

曹国栋, 曹芳. PI3K/AKT/mTOR信号通路及相关表观遗传调控机制在结直肠癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(2): 148-153.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] XIE Y H, CHEN Y X, FANG J Y. Comprehensive review of targeted therapy for colorectal cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 22.
[3] NARAYANANKUTTY A. PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence [J]. Curr Drug Targets, 2019, 20(12): 1217-1226.
[4] YANG Q, JIANG W, HOU P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation[J]. Semin Cancer Biol, 2019, 59: 112-124.
[5] BRADLEY D. Biography of lewis C. cantley[J]. Proc Natl Acad Sci USA, 2004, 101(10): 3327-3328.
[6] FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/ mTOR signaling in gastric cancer: epigenetics and beyond[J]. Life Sci, 2020, 262: 118513.
[7] SALMENA L, CARRACEDO A, PANDOLFI P P. Tenets of PTEN tumor suppression[J]. Cell, 2008, 133(3): 403-414.
[8] SANAEI M J, BAGHERY SAGHCHY KHORASANI A, POURBAGHERISIGAROODI A, et al. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles[J]. J Cell Physiol, 2022, 237(3): 1720-1752.
[9] HUANG H, PARK S, ZHANG H B, et al. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo[J]. J Exp Clin Cancer Res, 2021, 40(1): 114.
[10] BACH D H, LONG N P, LUU T T, et al. The dominant role of forkhead box proteins in cancer[J]. Int J Mol Sci, 2018, 19(10): 3279.
[11] DAS V, BHATTACHARYA S, CHIKKAPUTTAIAH C, et al. The basics of epithelial-mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective[J]. J Cell Physiol, 2019, 234(9): 14535-14555.
[12] CHIN Y R, TOKER A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer[J]. Cell Signal, 2009, 21(4): 470-476.
[13] VERMANI L, KUMAR R, KANNAN R R, et al. Expression pattern of ALDH1, E-cadherin, Vimentin and Twist in early and late onset sporadic colorectal cancer[J]. Biomark Med, 2020, 14(14): 1371-1382.
[14] ABDEL RAOUF S M, IBRAHIM T R, ABDELAZIZ L A, et al. Prognostic value of TWIST1 and EZH2 expression in colon cancer[J]. J Gastrointest Cancer, 2021, 52(1): 90-98.
[15] FOERSTER E G, MUKHERJEE T, CABRAL-FERNANDES L, et al. How autophagy controls the intestinal epithelial barrier[J]. Autophagy, 2022, 18(1): 86-103.
[16] LI J K, SUN H T, JIANG X L, et al. Polyphyllin II induces protective autophagy and apoptosis via inhibiting PI3K/AKT/mTOR and STAT3 signaling in colorectal cancer cells[J]. Int J Mol Sci, 2022, 23(19): 11890.
[17] ESTÈVE P O, CHANG Y Q, SAMARANAYAKE M, et al. A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability[J]. Nat Struct Mol Biol, 2011, 18(1): 42-48.
[18] LIN P C, LIN J K, LIN H H, et al. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10(PTEN) loss in colorectal cancer[J]. World J Surg Oncol, 2015, 13: 186.
[19] WANG C, CHEN J X, KUANG Y Y, et al. A novel methylated cation channel TRPM4 inhibited colorectal cancer metastasis through Ca²⁺/ Calpain-mediated proteolysis of FAK and suppression of PI3K/Akt/ mTOR signaling pathway[J]. Int J Biol Sci, 2022, 18(14): 5575-5590.
[20] HUO M M, ZHANG J Y, HUANG W, et al. Interplay among metabolism, epigenetic modifications, and gene expression in cancer[J]. Front Cell Dev Biol, 2021, 9: 793428.
[21] FENG J T, CEN J H, LI J, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail[J]. Cell Adh Migr, 2015, 9(6): 495-501.
[22] CHEN X X, XU M, XU X N, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer[J]. Mol Cancer, 2020, 19(1): 106.
[23] SANCHES J G P, SONG B, ZHANG Q Q, et al. The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/ AKT pathway[J]. Front Oncol, 2021, 11: 637298.
[24] XU L J, ZHANG Y, WANG H, et al. Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway[J]. J Transl Med, 2014, 12: 244.
[25] DU G H, YU X L, CHEN Y, et al. miR-1-3p suppresses colorectal cancer cell proliferation and metastasis by inhibiting YWHAZmediated epithelial-mesenchymal transition[J]. Front Oncol, 2021, 11: 634596.
[26] QIN A C, QIAN W F. microRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression[J]. Int J Mol Med, 2018, 42(5): 2503-2514.
[27] MOAFIAN Z, MAGHROUNI A, SOLTANI A, et al. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer [J]. Mol Biol Rep, 2021, 48(5): 4797-4811.
[28] GHAZANCHAEI A, MANSOORI B, MOHAMMADI A, et al. Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer[J]. J Cell Physiol, 2018, 234(1): 769-776.
[29] CHEN Y Y, JIANG J W, ZHAO M Y, et al. microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway[J]. Oncotarget, 2016, 7(27): 41306-41319.
[30] XIONG B H, CHENG Y, MA L, et al. miR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells[J]. Int J Oncol, 2013, 42(1): 219-228.
[31] LIU H W, WANG J, TAO Y X, et al. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/ Akt pathways[J]. Life Sci, 2019, 221: 354-361.
[32] LAI C Y, YEH K Y, LIU B F, et al. microRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K/AKT, STAT3, and PDCD4/TNF-α signaling pathways in zebrafish[J]. Cancers (Basel), 2021, 13(21): 5565.
[33] NI H L, HAN Y J, JIN X H. Celastrol inhibits colon cancer cell proliferation by downregulating miR-21 and PI3K/AKT/GSK-3β pathway[J]. Int J Clin Exp Pathol, 2019, 12(3): 808-816.
[34] CORONEL-HERNÁNDEZ J, LÓPEZ-URRUTIA E, CONTRERASROMERO C, et al. Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis[J]. Cancer Cell Int, 2019, 19: 80.
[35] KE T W, WEI P L, YEH K T, et al. miR-92a promotes cell metastasis of colorectal cancer through PTEN-mediated PI3K/AKT pathway[J]. Ann Surg Oncol, 2015, 22(8): 2649-2655.
[36] QIN Y, HUO Z B, SONG X, et al. miR-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/AKT signaling pathway[J]. Oncol Lett, 2018, 15(3): 3197-3201.
[37] ZHENG L, ZHANG Y Q, LIU Y, et al. miR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer[J]. J Transl Med, 2015, 13: 252.
[38] YANG C G, DOU R Z, WEI C, et al. Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis[J]. Mol Ther, 2021, 29(6): 2088-2107.
[39] XUE Y, MA G X, GU D Y, et al. Genome-wide analysis of long noncoding RNA signature in human colorectal cancer[J]. Gene, 2015, 556(2): 227-234.
[40] SHAO Q W, XU J, DENG R, et al. Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer[J]. Biochem Biophys Res Commun, 2018, 495(1): 539-545.
[41] MENG S, JIAN Z, YAN X F, et al. LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer[J]. Mol Med Rep, 2019, 20(3): 2541-2548.
[42] SHANG A Q, WANG W W, YANG Y B, et al. Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 317(2): G222-G232.
[43] LIU B, PAN S M, XIAO Y, et al. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 316.
[44] ZHANG Y, LIU X X, ZHANG J Y, et al. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway[J]. Aging (Albany NY), 2020, 12(7): 5640-5650.
[45] DENG X, KONG F Y, LI S, et al. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer[J]. Cell Death Dis, 2021, 12(5): 485.
[46] SUN L N, FANG Y, WANG X, et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44[J]. Theranostics, 2019, 9(26): 8409-8425.
[47] HUANG K C, CHIANG S F, CHEN W T, et al. Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer[J]. Cancers (Basel), 2020, 12(2): 462.